Cost effectiveness and strategic planning (WHO-CHOICE)

AFR D: Cost effectiveness results for Malaria

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2000.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
MAL-1 : Insecticide-treated bed nets (ITN) 95% 0.86 30,171 29 Dominated
MAL-2 : Intermittent presumptive treatment in pregnancy (IPTP) 95% 0.08 313 247 Dominated
MAL-3 : Indoor residual spraying (IRS) 95% 0.96 30,171 32 Dominated
MAL-4: Case management with chloroquine (CQ) 95% 0.32 13,336 24 Dominated
MAL-5 : Case management with sulfadoxine-pyrimethamine (SP) 95% 0.32 21,928 15 Dominated
MAL-6 : Case management with non-artemisinin-based combination therapy (Comb) 95% 0.32 23,920 13 Dominated
MAL-7 : Case management with artemisinin-based combination therapy (ACT) 95% 0.33 31,470 10 16
MAL-8 : Combination (ITN & CQ) 95% 1.07 36,086 30 Dominated
MAL-9 : Combination (ITN & SP) 95% 1.07 39,875 27 Dominated
MAL-10 : Combination (ITN & Combo) 95% 1.07 40,750 26 Dominated
MAL-11 : Combination (ITN & ACT) 95% 1.07 44,062 24 Dominated
MAL-12 : Combination (IRS & CQ) 95% 1.15 36,086 32 Dominated
MAL-13 : Combination (IRS & SP) 95% 1.15 39,875 29 Dominated
MAL-14 : Combination (IRS & Combo) 95% 1.15 40,750 28 Dominated
MAL-15 : Combination (IRS & ACT) 95% 1.15 44,062 26 Dominated
MAL-16: Combination (IRS & ACT & IPTP) 95% 1.15 44,115 26 Dominated
MAL-17: Combination (ITN & ACT & IPTP) 95% 1.07 44,115 24 59
MAL-18: Combination (IRS & ITN) 95% 1.51 43,105 35 Dominated
MAL-19: Combination (IRS & ITN & ACT) 95% 1.59 49,494 32 Dominated
MAL-20: Combination (IRS & ITN & ACT & IPTP) 95% 1.59 49,518 32 96
MAL-21: Insecticide-treated bed nets (ITN) 80% 0.76 25,943 29 Dominated
MAL-22: Intermittent presumptive treatment in pregnancy (IPTP) 80% 0.06 264 237 Dominated
MAL-23: Indoor residual spraying (IRS) 80% 0.81 25,943 31 Dominated
MAL-24: Case management with chloroquine (CQ) 80% 0.24 11,216 21 Dominated
MAL-25: Case management with sulfadoxine-pyrimethamine (SP) 80% 0.24 18,429 13 Dominated
MAL-26: Case management with non-artemisinin-based combination therapy (Comb) 80% 0.24 20,100 12 Dominated
MAL-27: Case management with artemisinin-based combination therapy (ACT) 80% 0.25 26,426 9 9
MAL-28: Combination (ITN & CQ) 80% 0.89 31,573 28 Dominated
MAL-29: Combination (ITN & SP) 80% 1.00 35,176 28 Dominated
MAL-30: Combination (ITN & Combo) 80% 0.89 36,009 25 Dominated
MAL-31: Combination (ITN & ACT) 80% 1.00 39,157 26 Dominated
MAL-32: Combination (IRS & CQ) 80% 0.94 31,573 30 Dominated
MAL-33: Combination (IRS & SP) 80% 0.94 35,176 27 Dominated
MAL-34: Combination (IRS & Combo) 80% 0.94 36,009 26 Dominated
MAL-35: Combination (IRS & ACT) 80% 0.94 39,157 24 Dominated
MAL-36: Combination (IRS & ACT & IPTP) 80% 0.94 39,207 24 Dominated
MAL-37: Combination (ITN & ACT & IPTP) 80% 0.89 39,207 23 Dominated
MAL-38: Combination (IRS & ITN) 80% 1.31 37,826 35 Dominated
MAL-39: Combination (IRS & ITN & ACT) 80% 1.38 45,098 31 Dominated
MAL-40: Combination (IRS & ITN & ACT & IPTP) 80% 1.39 45,125 31 Dominated
MAL-41: Insecticide-treated bed nets (ITN) 50% 0.57 16,873 34 Dominated
MAL-42: Intermittent presumptive treatment in pregnancy (IPTP) 50% 0.06 165 355 Dominated
MAL-43: Indoor residual spraying (IRS) 50% 0.51 16,873 30 Dominated
MAL-44: Case management with chloroquine (CQ) 50% 0.22 6,993 31 Dominated
MAL-45: Case management with sulfadoxine-pyrimethamine (SP) 50% 0.22 11,473 19 Dominated
MAL-46: Case management with non-artemisinin-based combination therapy (Comb) 50% 0.22 12,508 17 Dominated
MAL-47: Case management with artemisinin-based combination therapy (ACT) 50% 0.22 16,422 13 Dominated
MAL-48: Combination (ITN & CQ) 50% 0.66 21,183 31 Dominated
MAL-49: Combination (ITN & SP) 50% 0.87 23,938 36 Dominated
MAL-50: Combination (ITN & Combo) 50% 0.66 24,574 27 Dominated
MAL-51: Combination (ITN & ACT) 50% 0.87 26,977 32 Dominated
MAL-52: Combination (IRS & CQ) 50% 0.65 21,183 31 Dominated
MAL-53: Combination (IRS & SP) 50% 0.65 23,938 27 Dominated
MAL-54: Combination (IRS & Combo) 50% 0.65 24,574 27 Dominated
MAL-55: Combination (IRS & ACT) 50% 0.66 26,977 24 Dominated
MAL-56: Combination (IRS & ACT & IPTP) 50% 0.66 27,015 24 Dominated
MAL-57: Combination (ITN & ACT & IPTP) 50% 0.66 27,015 24 Dominated
MAL-58: Combination (IRS & ITN) 50% 0.91 25,503 36 Dominated
MAL-59: Combination (IRS & ITN & ACT) 50% 0.99 32,342 30 Dominated
MAL-60: Combination (IRS & ITN & ACT & IPTP) 50% 0.99 32,368 30 Dominated
Share